-
0
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Radiology2023-05-24 20:00:00
How are you managing your prostate cancer patients on active surveillance?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Bladder Cancer
821
global
1
1.25
9
1.25
1.25
Roundtable
0
1
Urology2023-05-22 20:00:00
Did you know that immunotherapy-based regimens are being used to treat patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) leading to improved outcomes?
1.25ABIM MOC
1.25CME/CE
75MIN
Save
-
Renal Failure
724
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Nephrology2023-03-21 20:00:00
Guideline-orientated management of immunoglobulin A nephropathy (IgAN) includes enrolling patients who remain proteinuric despite optimized standard of care in clinical trials.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Bladder Cancer
821
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-03-09 19:00:00
Get the latest data on prostate and bladder cancer from the 2023 winter meetings.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Renal Failure
724
global
1
0.5
0.5
Clinical Review
0
1
Nephrology2023-01-09 19:00:00
Did you know that 25 to 30 percent of patients with immunoglobulin A nephropathy (IgAN) will progress to end-stage kidney disease within 20 to 25 years of presentation?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Prostate Cancer
3003438
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Family Medicine/Primary Care2022-12-18 19:00:00
Did you know that screening for prostate cancer remains controversial? Listen to Dr Neal Shore discuss the latest on screening for prostate cancer.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
0
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Radiology2023-05-24 20:00:00
How are you managing your prostate cancer patients on active surveillance?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Bladder Cancer
821
global
1
1.25
9
1.25
1.25
Roundtable
0
1
Urology2023-05-22 20:00:00
Did you know that immunotherapy-based regimens are being used to treat patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) leading to improved outcomes?
1.25ABIM MOC
1.25CME/CE
75MIN
Save
-
Renal Failure
724
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Nephrology2023-03-21 20:00:00
Guideline-orientated management of immunoglobulin A nephropathy (IgAN) includes enrolling patients who remain proteinuric despite optimized standard of care in clinical trials.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Bladder Cancer
821
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2023-03-09 19:00:00
Get the latest data on prostate and bladder cancer from the 2023 winter meetings.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Renal Failure
724
global
1
0.5
0.5
Clinical Review
0
1
Nephrology2023-01-09 19:00:00
Did you know that 25 to 30 percent of patients with immunoglobulin A nephropathy (IgAN) will progress to end-stage kidney disease within 20 to 25 years of presentation?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Prostate Cancer
3003438
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Family Medicine/Primary Care2022-12-18 19:00:00
Did you know that screening for prostate cancer remains controversial? Listen to Dr Neal Shore discuss the latest on screening for prostate cancer.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Prostate Cancer
3003438
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-12-11 19:00:00
Did you know that recent advances in diagnostics are expanding access to non-invasive approaches to screening for prostate cancer?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Bladder Cancer
821
global
1
0.25
9
0.25
0.25
Roundtable
0
1
Hematology-Oncology2022-12-07 19:00:00
Are you aware of the most common presenting sign or symptom observed in patients with bladder cancer?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Human Papillomavirus
3029298
global
1
2.5
9
2.5
2
2.5
2.5
Roundtable
0
1
Ob/Gyn & Women's Health2022-11-28 19:00:00
Learn more about women’s health topics including HPV vaccines, menopause, endometriosis, STIs, CMV, and postpartum depression.
2.5ABIM MOC
2.5CME/CE
150MIN
Save
-
Uterine Leiomyoma
1539
global
1
2.0
9
2.0
2
2.0
2.0
Roundtable
0
1
Ob/Gyn & Women's Health2022-11-27 19:00:00
Learn more about women’s health topics including uterine fibroids, HIV, overactive bladder, HPV, and contraceptives.
2.0ABIM MOC
2.0CME/CE
120MIN
Save
-
Prostate Cancer
3003438
global
1
0.5
9
0.5
2
0.5
3
0.5
0.5
Roundtable
0
1
Hematology-Oncology2022-11-21 19:00:00
Do you know which class of agents used for androgen deprivation therapy (ADT) appears to have the most cardiovascular risk?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Bladder Cancer
821
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-11-07 19:00:00
Did you know that bladder cancer is highly treatable in the localized stages? Learn more about the latest in treating early-stage bladder cancer.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Prostate Cancer
3003438
global
1
0.5
9
0.5
0.5
Commentary
0
1
Hematology-Oncology2022-10-25 20:00:00
Are you up-to-date on the latest data in metastatic castration-resistant prostate cancer (mCRPC) from the 2022 European Society of Medical Oncology Congress?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Overactive Bladder
3004411
global
1
0.5
9
0.5
2
0.5
3
0.5
0.5
Roundtable
0
1
Urology2022-10-20 20:00:00
What should be considered when deciding on treatment for overactive bladder (OAB)? Join Drs Enemchukwu and Newman as they discuss how to treat the whole patient.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
0
global
1
0.75
9
0.75
0.75
Roundtable
0
1
Urology2022-09-28 20:00:00
Do you know which patients with overactive bladder (OAB) are at risk for experiencing anticholinergic burden? Join the experts to learn more.
0.75ABIM MOC
0.75CME/CE
45MIN
Save
-
Chronic Kidney Disease
727
global
1
0.25
9
0.25
2
0.25
8
0.25
0.25
Clinical Brief
0
1
Nephrology2022-09-22 20:00:00
Should socioeconomically deprived patients at high CKD risk be counseled about regular physical activity?
0.25ABIM MOC
0.25CME/CE
15MIN
Save
-
Overactive Bladder
3004411
global
1
0.5
9
0.5
2
0.5
3
0.5
0.5
Commentary
0
1
Urology2022-09-14 20:00:00
What is the best way to communicate with and manage complex patients with overactive bladder (OAB)? Join Drs Varano, Dmochowski, and Newman as they provide their insights.
0.5ABIM MOC
0.5CME/CE
30MIN
Save
-
Prostate Cancer
3003438
global
1
0.5
9
0.5
0.5
Roundtable
0
1
Hematology-Oncology2022-09-14 20:00:00
Did you know that treatment intensification has been shown to improve outcomes for patients with hormone-sensitive prostate cancer (HSPC)?
0.5ABIM MOC
0.5CME/CE
30MIN
Save
